Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell Differentiation
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Inhibitors of histone deacetylase (HD) bear great potential as new drugs due to their ability to modulate transcription and to induce apoptosis or differentiation in cancer cells. We have described previously analogues of the complex natural HD inhibitors trapoxin B and trichostatin A with activities in the submicromolar range. Here we report structure-activity relationship analyses of further analogues of trichostatin A with respect to in vitro inhibition of maize HD-2 and their ability to induce terminal cell differentiation in Friend leukemic cells. This is the first report that shows the correlation between HD inhibitory activity and action on cancer cells on a larger series of similar compounds. Only the compounds that inhibit HD induce differentiation and/or exert antiproliferative activities in cell culture. Our studies support the use of in vitro systems as screening tools and provide structure-activity relationships that merit further investigation of this interesting target.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These inhibitors are active against class I and class II HDACs, and have the ability to induce multiple effects within cells, including cell differentiation, induction of cell cycle arrest, and suppression of tumor growth (Jung et al., 1999; Almenara et al., 2002; Richon et al., 1998; Yoshida et al., 1990a, 1990b).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Jung et al., 1999
Citations
Cites
Cell Biology: a Laboratory Handbook
Harris, A. (1995) · Journal of Medical Genetics · doi:10.1136/jmg.32.9.759 · Cited by 1,225
Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamir, I., et al. (1998) · Nature · doi:10.1038/35901 · Cited by 1,004
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Borrow, J., Stanton, V. P., Andresen, J. M., Becher, R., Behm, F. G., Chaganti, R. S. K., Civin, C. I., Disteche, C., Dubé, I., Frischauf, A. M., et al. (1996) · Nature Genetics · doi:10.1038/ng0996-33 · Cited by 771
Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 694
Cellular Differentiation Regulated by Gibberellin in the Arabidopsis thaliana pickle Mutant
Ogas, J., Cheng, J.-C., Sung, Z. R., & Somerville, C. (1997) · Science · doi:10.1126/science.277.5322.91 · Cited by 344
Histones of Drosophila Embryos
Alfageme, C. R., Zweidler, A., Mahowald, A., & Cohen, L. H. (1974) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)42534-9 · Cited by 336
Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives
Suzuki, T., Ando, T., Tsuchiya, K., Fukazawa, N., Saito, A., Mariko, Y., Yamashita, T., & Nakanishi, O. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980565u · Cited by 293
Identification of Maize Histone Deacetylase HD2 as an Acidic Nucleolar Phosphoprotein
Lusser, A., Brosch, G., Loidl, A., Haas, H., & Loidl, P. (1997) · Science · doi:10.1126/science.277.5322.88 · Cited by 232
Self-citationHistone acetylation: facts and questions
Loidl, P. (1994) · Chromosoma · doi:10.1007/bf00337382 · Cited by 171
Self-citation
Research works printed but not linked: 11
- Pennisi E, 1997, Science, 275, 157
- Pazin M. J., 1997, Cell, 86, 328
- Liu R. J., 1998, Nature, 391, 814
- Jung M., 1997, Bioorg. Med. Chem. Lett., 7, 1658
- Yoshida M., 1990, J. Biol. Chem, 265, 17179
- He L. Z., 1998, Nature Genet., 18, 135
- Lea M. A., 1995, Anticancer Res., 15, 884
- Warrell, 1999, J. Natl. Cancer Inst., 90, 1625
- Hagmann W. K., 1996, Annu. Rep. Med. Chem., 31, 240
- Richon V. M., 1999, 90th Annual Meeting of the AACR, Apr 10−14
- Schmidt K., 1999, Inhibitors of histone deacetylase suppress the growth of MCF-7 breast cancer cells. Arch. Pharm. Pharm. Med. Chem
Cited by
Items 101–198 of 198
Jiao, J., Fang, H., Wang, X., Guan, P. F., Yuan, Y., & Xu, W. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.06.010 · Cited by 24
Eikel, D., Hoffmann, K., Zoll, K., Lampen, A., & Nau, H. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008078 · Cited by 25
“Here we demonstrated that VPA hydroxamates and amides are not HDAC inhibitors, unlike TSA and SAHA, which are HDAC inhibitors only as hydroxamates, but not as amides or carboxylic acids (Yoshida et al., 1990; Jung et al., 1999).”
BackgroundPapeleu, P., Wullaert, A., Elaut, G., Henkens, T., Vinken, M., Laus, G., Tourwé, D., Beyaert, R., Rogiers, V., & Vanhaecke, T. (2007) · Cell Proliferation · doi:10.1111/j.1365-2184.2007.00466.x · Cited by 23
“Me 2 N-BAVAH), a structural analogue of TSA, appears to be more stable in rat hepatocyte suspensions (Table 1; Elaut et al. 2004) and has previously been shown to inhibit HDAC activity and proliferation in Friend erythroleukaemia cells (Jung et al. 1999).”
BackgroundMethodInfluentialHistone deacetylase inhibitors in myelodysplastic syndrome
Bhalla, K. N., & List, A. F. (2004) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2004.08.011 · Cited by 27
Herp, D., Ridinger, J., Robaa, D., Shinsky, S. A., Schmidtkunz, K., Yesiloglu, T. Z., Bayer, T., Steimbach, R. R., Herbst‐Gervasoni, C. J., Merz, A., et al. (2022) · ChemBioChem · doi:10.1002/cbic.202200180 · Cited by 22
Self-citationWahi, A., Jain, P., Sinhari, A., & Jadhav, H. R. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02674-4 · Cited by 25
Jose, B., Okamura, S., Kato, T., Nishino, N., Sumida, Y., & Yoshida, M. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.01.014 · Cited by 21
Marson, C. M., Mahadevan, T., Dines, J., Sengmany, S., Morrell, J. M., Alao, J. P., Joel, S. P., Vigushin, D. M., & Coombes, R. C. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.09.085 · Cited by 24
Zhu, Y., Li, H., Lü, S., Zheng, Y.-X., Wu, Z., Tang, W., Zhou, X. Y., & Lu, T. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.01.010 · Cited by 22
Takai, N., Ueda, T., Nishida, M., Nasu, K., & Narahara, H. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.09.044 · Cited by 24
RetractedMayer, M., Berger, A., Leischner, C., Renner, O., Burkard, M., Böcker, A., Noor, S., Weiland, T., Weiß, T. S., Busch, C., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15040438 · Cited by 20
“The classical way to inhibit an HDAC is based on modeling of a HDAC pharmacophore and requires three elements (zinc binding group, linker, and cap) [61,71,72].”
Li, X., Liu, J., Yang, X., Lu, X., Zhao, T., Gong, H., & Zhu, H. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.05.031 · Cited by 19
HDAC inhibitor M344 suppresses MCF-7 breast cancer cell proliferation
Yeung, A., Bhargava, R. K., Ahn, R., Bahna, S. G., Kang, N. H., Lacoul, A., & Niles, L. P. (2011) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2011.06.007 · Cited by 15
Simoben, C. V., Ghazy, E., Zeyen, P., Darwish, S., Schmidt, M., Romier, C., Robaa, D., & Sippl, W. (2021) · Molecules · doi:10.3390/molecules26092584 · Cited by 17
Decroos, C., Bowman, C. M., & Christianson, D. W. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.05.045 · Cited by 17
The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer
Knoche, S. M., Brumfield, G. L., Goetz, B. T., Sliker, B. H., Larson, A. C., Olson, M. T., Poelaert, B. J., Bavari, A., Yan, Y., Black, J. D., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273518 · Cited by 16
“The HDAC inhibitor 4-dimethylamino-N-(6-hydroxycarbamoylhexyl)-benzamide (also known as M344 [28]), like vorinostat, is effective at submicromolar concentrations for inhibiting HDACs 1, 2, 3, and 6 [11, 29].”
BackgroundLi, X., & Chen, B. (2009) · American Journal of Biomedical Sciences · doi:10.5099/aj090400352 · Cited by 18
“recently by Jung and co-investigators [15].”
Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors
Angibaud, P. R., Arts, J., Emelen, K. V., Poncelet, V., Pilatte, I., Roux, B., Brandt, S. V., Verdonck, M., Winter, H. L. D., ten Holte, P., et al. (2005) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2005.01.008 · Cited by 16
Bapna, A., Vickerstaffe, E., Warrington, B. H., Ladlow, M., Fan, T., & Ley, S. V. (2004) · Organic & Biomolecular Chemistry · doi:10.1039/b313414h · Cited by 17
Ligand based pharmacophore modelling of anticancer histone deacetylase inhibitors
Noureen, N., Kalsoom, S., & Rashid, H. (2010) · AFRICAN JOURNAL OF BIOTECHNOLOGY · doi:10.5897/ajb2010.000-3268 · Cited by 15
“In developing potent histone deacetylase inhibitors, this three-component concept has proved to be successful (Jung et al., 1999; Sternson et al., 2001).”
BackgroundNatural Product Sources of Drugs: Plants, Microbes, Marine Organisms, and Animals
Cragg, G. M. L., & Newman, D. J. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00011-0 · Cited by 15
Fraczek, J., Vinken, M., Tourwé, D., Vanhaecke, T., & Rogiers, V. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9659-8 · Cited by 15
“6-[(4-pyrrolidine-1-ylbenzoyl) amino] hexanoic acid hydroxamate (4-PBN-HAH, AN-8) was synthesized as previously described [ 33 , 34].”
MethodGiacomelli, G., & Porcheddu, A. (2008) · Elsevier eBooks · doi:10.1016/b978-008044992-0.00803-8 · Cited by 15
Hölsken, A., Eyüpoglu, I. Y., Lueders, M., Tränkle, C., Dieckmann, D., Buslei, R., Hahnen, E., Blümcke, I., & Siebzehnrübl, F. A. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0082-8 · Cited by 17
“Various pharmacological substances have been identiWed as selective HDAC inhibitors, amongst which the second generation compounds suberoylanilide hydroxamic acid (SAHA), as well as MS-275 and M344 are most promising [25, 31, 33, 39].”
BackgroundCurrent patent status of histone deacetylase inhibitors
(2002) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.12.9.1375 · Cited by 15
“The structure – activity relationship (SAR) of some of the amide-varied analogues has been published by another group [10].”
Background5 Histone Deacetylase Inhibitors: A Novel Class of Anti-Cancer Agents on its Way to the Market
Körner, M., & Tibes, U. (2008) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(07)00005-7 · Cited by 13
Takai, N., Ueda, T., Nishida, M., Nasu, K., & Narahara, H. (2008) · International Journal of Molecular Medicine · doi:10.3892/ijmm.21.1.109 · Cited by 17
Nakao, Y., & Fusetani, N. (2010) · Elsevier eBooks · doi:10.1016/b978-008045382-8.00043-5 · Cited by 13
Fréchette, S., Leit, S. M., Woo, S. H., Lapointe, G., Jeannotte, G., Moradei, O. M., Paquin, I., Bouchain, G., Raeppel, S. L., Gaudette, F., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.057 · Cited by 13
Fraczek, J., Deleu, S., Lukaszuk, A., Doktorova, T. Y., Tourwé, D., Geerts, A. E., Vanhaecke, T., Vanderkerken, K., & Rogiers, V. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9180-x · Cited by 11
“The results shown in Table 1 confirm a previously made observation namely that the length of the aliphatic linker is a critical factor determining the potency of HDAC-I which could be related to the fact that compounds with a C5 spacer demonstrate more resemblance to the natural HDAC substrate, namely acetylated lysin…”
BackgroundWittich, S., Scherf, H. R., Xie, C., Heltweg, B., Dequiedt, F., Verdin, E. M., Gerhäuser, C., & Jung, M. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200507000-00008 · Cited by 12
Self-citationThe Discovery and Development of Belinostat
Finn, P. W., Loža, E., & Carstensen, E. (2016) · Wiley eBooks · doi:10.1002/9783527800315.ch3 · Cited by 14
Bülbül, E. F., Robaa, D., Sun, P., Mahmoudi, F., Melesina, J., Zessin, M., Schutkowski, M., & Sippl, W. (2023) · Pharmaceuticals · doi:10.3390/ph16070968 · Cited by 13
Pflieger, M., Sönnichsen, M., Horstick‐Muche, N., Yang, J. C., Schliehe‐Diecks, J., Schöler, A., Borkhardt, A., Hamacher, A., Kassack, M. U., Hansen, F. K., et al. (2021) · ChemMedChem · doi:10.1002/cmdc.202001011 · Cited by 10
Synthesis, antimalarial activity, and cellular toxicity of new arylpyrrolylaminoquinolines
Casagrande, M., Basilico, N., Rusconi, C., Taramelli, D., & Sparatore, A. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.08.001 · Cited by 11
Debnath, S., Debnath, T., Majumdar, S., Kalle, A. M., & Vema, A. (2015) · Research and Reports in Medicinal Chemistry · doi:10.2147/rrmc.s81388 · Cited by 13
“28 The inhibitors, which contain a cap group of cyclic tetrapeptide and a carboxylic acid functional group, 29,30 have proven to be crucial for HDAC inhibition.”
Nakao, Y., Yoshida, S., Matsunaga, S., Shindoh, N., Terada, Y., Nagai, K., Yamashita, J. K., Ganesan, A., van Soest, R. W. M., & Fusetani, N. (2006) · Angewandte Chemie · doi:10.1002/ange.200602047 · Cited by 9
Elaut, G., Török, G., Papeleu, P., Vanhaecke, T., Laus, G., Tourwé, D., & Rogiers, V. (2004) · Alternatives to Laboratory Animals · doi:10.1177/026119290403201s16 · Cited by 11
“This compound inhibits HDAC in the micromolar range and has been shown to induce differentiation in a number of dedifferentiated, proliferating cells (27, 29).”
BackgroundPeptidomimetics and metalloprotease inhibitors as anticancer drugs
Su, L., & Xu, W. (2009) · Science China Chemistry · doi:10.1007/s11426-009-0040-0 · Cited by 8
Hydroxamic Acids: Biological Properties and Potential Uses as Therapeutic Agents
Mai, A. (2010) · Wiley eBooks · doi:10.1002/9780470682531.pat0515 · Cited by 9
Micheletti, G., Boga, C., Drius, G., Bordoni, S., & Calonghi, N. (2024) · Molecules · doi:10.3390/molecules29010238 · Cited by 7
“2+ this reflective binding model was firstly proposed for HDAC inhibitors by Jung et al. [20,21].”
BackgroundLiao, V. W. Y., Liu, T., & Codd, R. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.006 · Cited by 8
Nature as Source of Medicines; Novel Drugs from Nature; Screening for Antitumor Activity
Cragg, G. M. L., & Newman, D. J. (2010) · Elsevier eBooks · doi:10.1016/b978-008045382-8.00057-5 · Cited by 8
Histone Deacetylase Inhibitors
JONES, P. G. (2009) · Methods and principles in medicinal chemistry · doi:10.1002/9783527627073.ch9 · Cited by 7
QSAR studies of histone deacetylase (HDAC) inhibitors by CoMFA, CoMSIA, and molecular docking.
Zhang, L. J., Fang, H., Zhu, H., Wang, Q., & Xu, W. (2009) · PubMed · Cited by 5
Smithson, D. C., Guiguemde, W. A., & Guy, R. K. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc234 · Cited by 6
Aromatic Amino Acid Hydroxylases as Off-Targets of Histone Deacetylase Inhibitors
Baumann, A., Papenkordt, N., Robaa, D., Szigetvari, P. D., Vogelmann, A., Bracher, F., Sippl, W., Jung, M., & Haavik, J. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00346 · Cited by 5
Self-citationHydroxamic Acids as Histone Deacetylase Inhibitors
Thaler, F., Patil, V. M., & Gupta, S. P. (2013) · Springer eBooks · doi:10.1007/978-3-642-38111-9_5 · Cited by 3
Córdova-Bahena, L., Cervantes, C., Soto-Arredondo, K. J., Martínez‐Alfaro, M., Zarco, N., Garcia-Revilla, M. A., Alcaraz‐Contreras, Y., Tirado, L. P., Vazquez, M. A., & Robles, J. (2018) · Journal of the Mexican Chemical Society · doi:10.29356/jmcs.v61i4.460 · Cited by 3
Elmezayen, A. D., Al-Obaidi, A., & Yelekçi, K. (2021) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2021.107937 · Cited by 4
Herp, D., Ridinger, J., Robaa, D., Shinsky, S. A., Schmidtkunz, K., Yesiloglu, T. Z., Bayer, T., Sehr, P. A., Gunkel, N., Miller, A. K., et al. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12440096.v3 · Cited by 2
Self-citationSynthesis of 2-quinolinecarboxamide derivatives as potential HDAC inhibitors
Habarova, O., Bobiļeva, O., Loža, E., & Romančikova, N. (2011) · Chemistry of Heterocyclic Compounds · doi:10.1007/s10593-011-0825-x · Cited by 2
Hadjipavlou‐Litina, D., & Pontiki, E. A. (2013) · Springer eBooks · doi:10.1007/978-3-642-38111-9_8 · Cited by 2
Deleu, S., Fraczek, J., Lukaszuk, A., Doktorova, T. Y., Tourwé, D. A., Geerts, A. E., Camp, B. V., Vanhaecke, T., & Rogiers, V. (2015) · Cited by 2
Henkens, T., Snykers, S., Vinken, M., Fraczek, J., Lukaszuk, A., Tourwé, D., Verheyen, G. R., Gompel, J. V., Vanparys, P., Rogiers, V., et al. (2010) · Toxicology in Vitro · doi:10.1016/j.tiv.2010.09.013 · Cited by 2
Epigenetic therapies: histone deacetylases
Blanquart, C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91367-6.00022-2 · Cited by 1
Tan, Y., Xiang, H., Jin, J., He, X., Li, S., & Ye, Y. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c02218 · Cited by 1
Jung, M. (2000) · Pharmazie in unserer Zeit · doi:10.1002/1615-1003(200012)29:6<385::aid-pauz385>3.0.co;2-3 · Cited by 2
Self-citationEntwicklung von Substraten und Inhibitoren pharmakologisch relevanter Proteintargets
Riester, D. (2005) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-1405 · Cited by 1
Radio-Sensitizing Effects of Novel Histone De-Acetylase Inhibitors in Prostate Cancer
Gupta, S., & Ahmed, M. M. (2005) · Defense Technical Information Center (DTIC) · doi:10.21236/ada446334
Hydroxamic Acid Derivatives as Potential Anticancer Agents
Gupta, M., Singh, G., & Gupta, S. (2013) · Springer eBooks · doi:10.1007/978-3-642-38111-9_7 · Cited by 1
Wegener, D. (2004) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-545 · Cited by 2
Molecular modelling studies of Histone Deacetylase inhibitors as anticancer agents
Narayanan, S., & Velmurugan, D. (2013) · Journal of Pharmacy Research · doi:10.1016/j.jopr.2013.07.017
Novel N-hydroxybenzamide histone deacetylase inhibitors as potential anti-cancer agents.
Jiao, J., Fang, H., & Xu, W. (2008) · PubMed
Brichta, L. (2006) · Kölner Universitäts PublikationsServer (Universität zu Köln)
Hauke, J. (2009) · Kölner Universitäts PublikationsServer (Universität zu Köln)
Targeting Selective Autophagy of Insoluble Protein Aggregates
Seneci, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801944-3.00005-9
Targeting (de)acetylation: A Diversity of Mechanism and Disease
Quaas, C. E., & Long, D. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00076-1
Yet, L. (2018) · Wiley eBooks · doi:10.1002/9781118686263.ch12
徐, 文., & 宿, 莉. (2008) · Scientia Sinica Chimica · doi:10.1360/zb2008-38-12-1043
Herp, D., Ridinger, J., Robaa, D., Shinsky, S. A., Schmidtkunz, K., Yesiloglu, T. Z., Bayer, T., Sehr, P. A., Gunkel, N., Miller, A. K., et al. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12440096 · Cited by 2
Self-citationKonsoula, Z., Cao, H., Velena, A., & Jung, M. (2023) · doi:10.1158/1535-7163.c.6532218.v1
Self-citationKonsoula, Z., Cao, H., Velena, A., & Jung, M. (2023) · doi:10.1158/1535-7163.c.6532218
Self-citationJung, M. (2002) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-59259-153-4_7 · Cited by 3
Self-citationM344 Suppresses Histone Deacetylase-Associated Phenotypes and Tumor Growth in Neuroblastoma
Brumfield, G. L., Doty, K. R., Knoche, S. M., Larson, A. C., Gephart, B. D., Coulter, D. W., & Solheim, J. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178494
Clinical Significance of Histone Deacetylase Inhibitors in Cancer
Shankar, S., & Srivastava, R. K. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-200-7_15
BindingDB Entry 50048539: Trifluoromethyl ketones as inhibitors of histone deacetylase.
BindingDB (2018) · UC San Diego · doi:10.7270/q26d5w6z
BindingDB (2018) · UC San Diego · doi:10.7270/q2ww7kw0
BindingDB (2018) · UC San Diego · doi:10.7270/q2c24zmw
BindingDB Entry 50048564: Heterocyclic ketones as inhibitors of histone deacetylase.
BindingDB (2018) · UC San Diego · doi:10.7270/q2zp4892
BindingDB Entry 50048585: Thiol-based SAHA analogues as potent histone deacetylase inhibitors.
BindingDB (2018) · UC San Diego · doi:10.7270/q28054sz
BindingDB Entry 50011356: Design and synthesis of a novel class of histone deacetylase inhibitors.
BindingDB (2009) · UC San Diego · doi:10.7270/q2sf2vf5
Metadata
- Authors
- Jung, M., Brosch, G., Kölle, D., Scherf, H., Gerhäuser, C., & Loidl, P.
- Affiliations
- German Cancer Research Center (DE)
- Corresponding author
- Jung, Manfred
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1999-10-15
- Volume
- 42
- Issue
- 22
- Pages
- 4669-4679
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2071513872
- Cited by
- 176
- References
- 18
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 4 · 2015: 3 · 2014: 5 · 2013: 6 · 2012: 4
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- histone deacetylase inhibitors, amide derivatives, structure-activity relationship, Friend leukemia cells, antiproliferative activity, anticancer drug discovery
- MeSH terms
- Animals, Cell Differentiation, Enzyme Inhibitors, Histone Deacetylases, Hydroxamic Acids, Models, Molecular, Structure-Activity Relationship, Tumor Cells, Cultured, Mice, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.